94 related articles for article (PubMed ID: 17932473)
1. PD and loss of peritoneal function.
Jörres A; Witowski J; Bender TO
Prilozi; 2007 Jul; 28(1):275-81. PubMed ID: 17932473
[TBL] [Abstract][Full Text] [Related]
2. PD membrane: biological responses to different PD fluids.
Jörres A; Witowski J
Contrib Nephrol; 2006; 150():48-53. PubMed ID: 16720991
[TBL] [Abstract][Full Text] [Related]
3. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions.
Topley N
Adv Ren Replace Ther; 1998 Jul; 5(3):179-84. PubMed ID: 9686628
[TBL] [Abstract][Full Text] [Related]
4. Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes?
Krishnan M; Tam P; Wu G; Breborowicz A; Oreopoulos DG
Int Urol Nephrol; 2005; 37(2):409-18. PubMed ID: 16142577
[TBL] [Abstract][Full Text] [Related]
5. Hypervolemia in peritoneal dialysis patients.
Lameire N; Van Biesen W
J Nephrol; 2004; 17 Suppl 8():S58-66. PubMed ID: 15599888
[TBL] [Abstract][Full Text] [Related]
6. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
7. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
Perl J; Nessim SJ; Bargman JM
Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal angiogenesis in response to dialysis fluid.
Rippe B
Contrib Nephrol; 2009; 163():60-66. PubMed ID: 19494596
[TBL] [Abstract][Full Text] [Related]
9. Isolation of interstitial fluid and demonstration of local proinflammatory cytokine production and increased absorptive gradient in chronic peritoneal dialysis.
Rosengren BI; Sagstad SJ; Karlsen TV; Wiig H
Am J Physiol Renal Physiol; 2013 Jan; 304(2):F198-206. PubMed ID: 23152294
[TBL] [Abstract][Full Text] [Related]
10. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.
Schwenger V; Morath C; Salava A; Amann K; Seregin Y; Deppisch R; Ritz E; Bierhaus A; Nawroth PP; Zeier M
J Am Soc Nephrol; 2006 Jan; 17(1):199-207. PubMed ID: 16319192
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
12. Protecting the peritoneal membrane in dialyzed patients.
Grzegorzewska AE
Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal dialysis solutions low in glucose degradation products: clinical experience and outcomes.
Diaz-Buxo JA
Adv Perit Dial; 2007; 23():132-4. PubMed ID: 17886619
[TBL] [Abstract][Full Text] [Related]
15. Morpho-functional study of peritoneum in peritoneal dialysis patients.
Bertoli SV; Buzzi L; Ciurlino D; Maccario M; Martino S
J Nephrol; 2003; 16(3):373-8. PubMed ID: 12832736
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
Higuchi C; Nishimura H; Sanaka T
Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
[TBL] [Abstract][Full Text] [Related]
17. Chemical and physiological relevance of glucose degradation products in peritoneal dialysis.
Mittelmaier S; Niwa T; Pischetsrieder M
J Ren Nutr; 2012 Jan; 22(1):181-5. PubMed ID: 22200439
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
[TBL] [Abstract][Full Text] [Related]
19. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis.
Hasuike Y; Moriguchi R; Hata R; Miyagawa K; Kuragano T; Aizawa M; Yamamoto S; Yanase K; Izumi M; Tanimoto T; Nakanishi T
Am J Nephrol; 2007; 27(6):622-9. PubMed ID: 17851230
[TBL] [Abstract][Full Text] [Related]
20. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
Zeier M; Schwenger V; Deppisch R; Haug U; Weigel K; Bahner U; Wanner C; Schneider H; Henle T; Ritz E
Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
